Last Chance to lock-in and Earn a 10X Profit TODAY In My Verseon Inc. SPV Fund
Last Chance to lock-in and Earn a 10X Profit TODAY In My Verseon Inc. SPV Fund
Deep Research + Patience + Transformational Change
= 810% Outperformance vs. SP 500 Index
Hi Reader,
Toby here. While the AI revolution is NOT over, most of our recommended AI tech stack stocks are up over 3-6X in total since we added our "AI Tech Stack" positions due to AI tech mania and are mostly priced for perfection.
So where am I putting MY cash and money management clients from taking massive AI tech stack profits?
Verseon International Inc.--Because the pre-IPO Shares in my Verseon International SPV Fund ARE Now Worth 10X Our COST Basis!
This is the last call for my Friends and Family to Lock In This Incredible 10X Return TODAY and Own pre-IPO Verseon International Inc. Shares into a Late 2025 IPO with a 30-50X Upside Possible!
YO! This email is ALL about ME not getting an earful from you: "So WHY did you NOT get me into that pre-IPO Verseon Fund you sponsored for your subscribers and money management clients?"
And YES—over the years, friends who are self-directed investors (mostly) have chewed me out starting in the late 90s for not letting them know about a pre-IPO investment fund I put together for Xoom.com, which, during the internet mania, went from our cost basis of $2.50 to $78 post-IPO.
Or, after meeting Michael Saylor of Microstrategy in 1999 to help me set up InvestorPlace.com for Phillips Publishing, I put out a MUST BUY recommendation on $MSTR stock at around $15 a share, and it raced to >$340 in less than a year in the internet stock mania (lol, true story—a few Phillips Publishing employees RETIRED by banking high six-figure profits on $10k in the name).
And make no mistake—I have been chewed out for not telling subscribers or friends in small-cap tech stocks to SELL THEM or for a few deals over the last 25 years that did not work.
But this email is to make sure YOU understand the most important technology company I have discovered in the last 30 years as a financial research publisher/editor/hedge fund manager/mutual fund manager—and why you have a week or so to get in this fund I created so my subscribers, friends, and business associates!
The list you are comprises a fantastic crew of East and West Coast friends, long-time subscribers, and business associates I have collected as an equity analyst, Fox News contributor 2000-2014/ mutual/hedge fund/SPV manager, and investment newsletter publisher/editor for 25 years.
What's the big deal? The big deal is I am about to share with you a sentence I have never been able to type/speak about ANY investment EVER:
"Your investment into my TransMed One/TSIG LLC ($minimum $25,000+ for Friends & Family--I am in for $125K)--which owns Round D private stock in the most exciting bioscience company in the world--Verseon International Inc. in Fremont CA . . .
... means you will own Verseon's Pre-2025 IPO Preferred Round D shares at a pre-money valuation of just $334 million, which . . .
. . . with next week's new investment of $80 million via the bioscience fund run by former SVP at Johnson & Johnson Richard Serbin (whose primary investor is the CEO and Chairman of Johnson & Johnson Pharmaceuticals ticker JNJ)
. . . Verseon will be valued at a $3.2 billion pre-money valuation or @ a 10X higher valuation of the preferred shares and YOU CAN BE AN OWNER OF Verseon Round D shares at just a $334MM pre-money cost basis.
This is NOT a typo!
OBVIOUSLY, I (nor anyone) has been able offer an individual investor a locked-in INSTANT 10X return on any investment--until today!
But there are 9 OTHER COMPELLING reasons why IF YOU have risk capital to spare (and are an accredited investor), you would be crazy, in my opinion, NOT to get into my "Special Purpose Vehicle" aka SPV for Verseon International (the company which I have been a Board of Advisors members since September 2023).
This is truly a once-in-a-lifetime locked-in investment return. Yet, the news about Verseon's game-changing drug development platform gets better and better every week.
Reason to Invest 2) A new $150 million investment commitment comes into Verseon Pre-IPO Round D later this year by a significant South Korean bioscience fund (which I have seen the contract but cannot disclose) will come in at an even higher $3.7 billion pre-money valuation
Reason to Invest 3) Verseon has also recently secured a $2 billion follow-on Pre-IPO investment commitment from a $10 billion bioscience capital fund under Dr. Thomas A. Cellucci, MBA, who drove America’s nanotechnology/quantum computing agenda under Presidents Clinton and George W. Bush (who also served as US Federal Government's first-ever Chief Commercialization Officer at the US Department of Homeland Security (DHS) under both the Bush and Obama administrations)
Reason to Invest 4) Then read the praise of Pfizer’s former Senior vice president of R&D Strategy, Robert Karr, for Verseon's breakthrough drug development platform, who points out in a recent Forbes article on Verseon that Verseon's seamless patented drug discovery platform incorporates propriety advances in physics and AI, “Verseon's disruptive platform changes how drugs can be discovered and developed, and the company is poised to make a dramatic impact on modern medicine."
Here is the full article https://www.forbes.com/sites/chuckbrooks/2024/10/22/future-medicine-physics-biology-and-ai-will-transform-human-health/
Reason to Invest 5) After an extensive examination of Verseon's drug-discovery platform, Nobel Laureate Hartmut Michel said of Verseon's breakthrough quantum physics + AI drug development platform, “The fundamental advancements Verseon has made in quantum mechanical modeling of protein-drug interactions are extremely impressive.”
LOL, as I have shared for nearly a year, don't take my expertise on advanced quantum physics and new drug molecule development—take the advice of the experts in the fields and Nobel Prize winners who are putting $millions of THEIR MONEY into Verseon, which again is today at a 10X higher in pre-money valuation than my TransMed/TSIG LLC cost basis.
Reason to Invest 6) To make my point as clearly as I can to subscribers/friends and family (on just the $3.2 billion pre-money valuation in the latest VC round)
Just $10,000 in TransMed One LLC today (for accredited investors) or TSIG LLC (for non-accredited investors) is worth $100,000 TODAY based on the $3.2 billion pre-money valuation.
$25,000 in TransMed One LLC today (for accredited investors) or TSIG LLC (for non-accredited investors) is worth $250,000 TODAY based on the $3.2 billion pre-money valuation that new money is valuing Verseon at today.
$50,000 in TransMed One LLC today (for accredited investors) or TSIG LLC (for non-accredited investors) is worth $500,000 TODAY based on the Celluci Group's $3.2 billion pre-money valuation.
PS: I added $50k more of my ROTH retirement money to TransMed One LLC this week. If you want to invest IRA money in my LLCs, Madison Trust will make that happen--they researched and approved my fund for investment in IRA's that they administrate!
Contact: Zach at Madison Trust
Investments Support Specialist
The Madison Trust Investments Team
PLEASE SCHEDULE A CALL HERE
E: investments@madisontrust.com
P: 845.947.1000
F: 845.947.1212
Action to Take to NOT MISS This 10X+ Pre-IPO Opportunity: TEXT ME/EMAIL ME/CALL ME to reserve a space in my TransMed One LLC fund Text/Mobile 301 4128622 Email tsmith@transformityresearch.com
How does it work that you can invest in TransMed One LLC, now sitting on a nearly 10X pre-IPO appreciation in our Verseon Round D Shares by the end of this week (with a little wiggle room next week!)?
Simple--TransMed One LLC is the ONLY investor in Verseon's D round who holds Verseon's $5 Convertible Preferred shares AND the equal number of 10 ten-cent warrants on Round D's $5 private placement shares at just a $334 million pre-money valuation :)
Reason to Invest 7) Remember that the last round's $3.7 billion pre-money valuation is BEFORE the blockbuster IPO. I am personally working with my contacts with Goldman Sachs/Morgan Stanley bioscience investment bankers for late 2025 or early 2026 blockbuster IPO and
Reason to Invest 8) The IPO Bankers at Goldman and Morgan Stanly say that "based on the 16 drug molecules Verseon has in the FDA approval pipeline, Verseon should IPO at $7-8 billion valuations at the low end--$10-$12 billion at the high end.
Do that math- $334 million turns into $10-$12 BILLION. What is the return on your investment?
So you may be asking, "How did Toby get an additional $2 million of Round D Preferred Shares + .10 Warrants for my TransMed One LLC (for accredited investors) and TSIG LLC (for non-accredited investors)?
The answer is simple: It's a reward for my firm, Transformity Capital Markets LLC, for raising the $5 million Verseon in the last 12 months. They needed the runway to get their results and story sound enough to secure the $billions of private venture capital in 2024 and the data they need for a late 2025-26 IPO!
The Quick Verseon Back Story: YEA, I know it SOUNDS Too Good To Be True--BUT the Story Gets Even Better!
Verseon (again of which I am on the Board of Advisors) built all its breakthrough drug development technology IN-HOUSE in order for to be the first drug development platform that can design never-before-made novel drug molecules on the computer.
The company’s KILLER VALUE PROPOSITION is its proprietary massive advances in quantum-physics modeling, now named Deep Quantum Modeling™ (DQM™).
DQM's secret sauce is simple: it's the only computer modeling technology in the world (developed and patented in-house over the last 10 YEARS) that accurately determines whether its computationally designed new drug molecules will bind to a targeted protein (i.e., cure/halt the disease) BEFORE making and testing the actual synthesized molecule in the lab.
Key Point: The capability to digitally create and test a new drug molecule has never existed in the global world of new drug development. DQM quite literally would save hundreds of $millions in failed clinical trials for Big Pharma (see below why Big Pharma fails 98% of the time to get a new drug from the test tube to FDA approval with $2+ Billion in money flushed down the drain in the process).
Next, Verseon's proprietary AI technology, trained on data from these new molecules identified by DQM, will help generate more 100% unique variants from which Verseon will select the best ones to introduce into FDA clinical trials.
The Really, Really Key Point: What Verseon has created has NEVER EXISTED in the drug development industry--they now have a never-before-possible proprietary "technology flywheel effect" where every new novel drug molecule created by Verseon makes the NEXT unique novel molecule even BETTER—and so on and so on!
Why is this technology worth $7-$10 BILLION to Big Pharma? It's simple- since NO OTHER drug developer sees Verseon's proprietary drug molecules, they don't know they exist. You prolly don't know this but the existing drug development industry is limited to @ 10,000-ish raw chemicals ("chemotypes") to create new drugs from . . .
. . . while Verseon has a "trillion trillion" drug molecule combinations in Verseon's proprietary DQM system.
For the math nerds, here is the math on the potential for building new drug molecules from an atom-by-atom universe exclusively available to Verseon to create order-of-magnitude 100% novel and order-of-magnitude more powerful + targeted drugs.
Key point: Unless a major global pharma company buys Verseon for, say, $20 billion ( that is their asking price!), Big Pharma will always be "fishing in a tiny droplet of 10,000 ish drug chemicals vs. Verseon's vast ocean of trillions of novel drug combinations!"
I bet you need to be made aware of Big Pharma's genuinely awful track record of just two new drugs approved for every 100 attempts at an average cost/money down the drain of $2.3 billion (including the cost of the 98 failures).
This is why Big Pharma is FIRING tens of thousands of drug development staff globally in 2024 (search ChatGPT or your favorite generative AI app for "Big Pharma research staffing cuts in 2024").
Here is a snippet of the carnage at Big Pharma R&D staffing cuts from a recent article from the Wall Street Journal Pulitzer Prize-winning pharmaceutical reporter David Wainer
"Big Pharma Scales Back R&D, Sending SHUDDERS Through Industry."
" Charles River Laboratories International, which provides drug-development services, plunged 12.6% on Wednesday, the most in four years, after sounding the alarm over pharma research spending plans. The Massachusetts-based company said it now expects to post a decline in sales for the full year, primarily owing to lower demand from pharma clients. The company was previously expected to grow this year. “There are profound cuts at pharmaceutical companies,” James Foster, Charles River’s chief executive officer, told analysts. Foster called the reduction in pharma research spending “unusual” and “sudden.”
Foster said his clients blame the cuts on the Inflation Reduction Act, which allows Medicare to negotiate some drug prices directly with manufacturers, and a looming patent cliff, which will see more than $200 billion in annual drug sales come under threat from copycat generics in the next 24 months.
However, for the past few years, pharma companies have warned that they might need to cut back on innovation as the U.S. government forces some companies to negotiate prices of their top-selling drugs. There was always some level of bluster to those comments, but a sharp decline in early research lends some credence to the claims.
More pointedly, several prominent pharmaceutical companies’ stocks have been hammered recently as their key profit-making drugs face competition or go off-patent. In response, management is cutting costs aggressively. Bristol-Myers and Pfizer are two prominent examples. Analysts expect both companies to see sales contracts later this decade. In May, Pfizer announced a new multiyear cost-cutting program that will save about $1.5 billion by the end of 2027. That is on top of an existing $4 billion cost-cutting effort announced this past year. Bristol-Myers recently said it would cut 2,200 jobs this year as part of an effort to save $1.5 billion by the end of 2025.
Cost cuts can juice earnings in the short term and boost stock prices. Both Pfizer and Bristol-Myers have been up in recent weeks. But if done too aggressively, they can cause harm. Cuts to marketing efforts could lead to lower future sales and cuts to R&D could lead to less innovation. Clinical trials were already on a downward trajectory post-COVID.
According to data from Iqvia, a major health analytics provider, the number of clinical trials started in 2023 was down 22% from 2021." Here is a free look at the entire article: https://www.wsj.com/health/pharma/big-pharma-cuts-r-d-sending-shudders-through-industry-18fc4cf0?st=WQSdW8&reflink=desktopwebshare_permalink
The BIG NEWS? Into the Big Pharma drug development ABYSS Steps Verseon with the $Multi-Trillion Quantum Physics + AI Solution for a $20 Trillion Problem (for Big Pharma stockholders and patients)
With a $20 trillion global market cap at serious risk, Big Pharma finally admits that since 98% of its new drug candidates fail to get FDA approval, resulting in an average loss of $895 million per failed drug, they have NO CHOICE but to acquire promising Phase II drug companies!
What is the result of this "come to Jesus" moment for Big Pharma?
The result is the huge wave of billions of $dollars now spent by Big Pharma on small biotech acquisitions in the last 24 months that is staggering, according to the latest pharma media reports:
Big Pharma has spent approximately $184 billion on mergers and acquisitions in the pharmaceutical industry over the last 12 months. source
📈 Record Deal Value In 2023, the top 10 M&A deals alone reached a combined value of $115.8 billion, further showcasing the high stakes in this sector.
And ALL the ABOVE IS WHY Verseon's Media Coverage is on FIRE!
In just the last 90 days, bioscience and business media coverage of Verson's revolutionary drug development platform has skyrocketed—for a very important reason!
Here is a snippet of a recent article in Forbes magazine: "Given that most major diseases are associated with aging, regulating the functions of proteins in our bodies will allow medicine to preserve a youthful and disease-free state far longer than is possible today—and eventually even partially rejuvenate our bodies from the cellular level.
These advances may make it possible to turn 80, 90, or even 100 into the new 50. But even before such dramatic increases in human health span happen, progress toward addressing large subsets of the druggable proteome will deliver a steady flow of amazing new drugs. These drugs will treat many diseases far better than we can today.
With Verseon's game-changing drug development platform, the 21st century will indeed establish itself as the century of biology."
The clincher is this conclusion: "Verseon's disruptive platform fundamentally changes how drugs can be discovered and developed, and the company is poised to make a dramatic global impact on modern medicine."
Here is the complete Forbes article: click here.
Reason to Invest 9) But here is the best explanation YET of why I am so bullish on the near future for Verseon and the incredible wealth-building opportunity for YOU to support a genuinely world-changing company at the pre-IPO level:
"Given that most major diseases are associated with aging, regulating the functions of proteins in our bodies will allow medicine to preserve a youthful and disease-free state far longer than is possible today—and eventually even to partially rejuvenate our bodies from the cellular level.
These advances in Verseon's groundbreaking drug development may make it possible to turn 80, 90, or even 100 into the new 50. But even before such dramatic increases in human health span happen, progress toward addressing large subsets of the druggable proteome will deliver a steady flow of amazing new drugs".
And the killer conclusion? "Verseon's drugs will treat many diseases far better than we can today. Then, the 21st century will indeed establish itself as the century of biology.
Wow :)
IF you need more evidence to invest in Verseon/invest MORE in Verseon, click this link and continue to be blown away by ALL that is being written and reported said about what I have come to call "The Proprietary Verseon Drug Development Flywheel."
https://www.verseon.com/news.html
My Final Point: All the above is why, in conversations with Dr. Thomas A. Cellucci (who is leading the $2 billion rounds at higher valuations next year), Tom says this: "Toby, when the investment and pharmaceutical world sees the Verseon Drug Development FlyWheel, I believe Verseon will become the most valuable company in the world.
And not the most valuable DRUG company--the most valuable company in the world, period!"
His logic is spot on! You see now that the unique proprietary molecules created by Verseon's DQM, in turn, vastly expand the potential for ever MORE powerful new drug molecules exponentially. In other words, the BETTER the latest 100% novel molecules created by DQM GET, the farther Verseon's drugs are ahead of the existing chemistry-based drug developers.
In turn, the FASTER development of Verseon's proprietary drug molecules, which address most of the world's $1.7 trillion of worldwide disease categories, means a MUCH faster FDA approval process too!
And with the fastest-aging world population in history—boy, does the world need Verseon NOW! The pharmaceutical spending annually is mind-blowing but not surprising in such a fast-aging world. In 2022, worldwide spending on pharmaceuticals reached approximately $1.48 trillion US dollars, a near double-digit increase from $887 billion US dollars in 2010.
And truly, only Verseon's breakthrough revolution in more effective drugs, which is happening at light speed vs. Big Pharma, can make a big difference in global health and longevity!
The proof of this claim is simple: A) Verseon's 16 unique drug molecules ALREADY address over $trillion of the world's annual disease spending. B) each of Verseon's 16 drugs and 8 categories has already achieved FDA Fast Track Status!
Now, according to an FDA official I recently contacted, 100% Fast Track Status for 16 drug molecules has never happened in the history of the FDA for ANY drug developer since the threshold to get the "FTS" is "the drug candidate must be a highly unique molecule compared to the existing standard of care."
Conclusion: So...hmmm...are you really surprised that multiple major J&J and Pfizer executives are investing their own money into Verseon pre-IPO funding rounds? Or that major bioscience funds are investing billions in Verseon in the final pre-IPO fundraisings?
Reason 10) to Become a Verseon Investor TODAY! What these Big Pharma leaders are doing should be obvious: They are gaining early access to Verseon to NOT to miss the "Holy Grail" of pharmaceutical science, which is high-quality-of-life extension—as the recent Forbes article states (here is the link to the entire article again).
Action to Take TODAY: You have this WEEK to COMMITT to my Verseon International with either my Accredited or Non-Accredited Special Purpose Vehicles (“SPV”) into this pre-IPO Round D Private Placement at a nearly 2x discount (my negotiated access to the “Friends and Family” portion of the round) to the $5 per share for the main round.
FIRST You HAVE TO complete online these investment/subscription agreements·
Accredited investors go to https://docuseal2.verseon.com/d/8S7VNSbWAmWonD
Non-Accredited investors go to https://docuseal.co/d/C6DvdoHXzgDUVN
Join me to make sure you buy enough TransMed One LLC or TSIG LLC shares today to make a difference in your net worth before this last tranche sells out!
To reserve your shares,
A) IMMEDIATELY TEXT me at 301 412-8622 or email me at tsmith@transformityresearch.com
B) Tell me how much you are in for
C) Get ready to wire funds ASAP this week or early next week (wiring details are in the subscription documents)
D) IF you have an accredited investor family or friend who you think would be a likely investor in TransMed One LLC--FEEL FREE to forward this email to them in the next 24 hours.
IF you need additional questions answered, TEXT ME at (301) 412-8622 to schedule a call ASAP!
Tobin Smith--Founder/CIO Transformity Research/Wealth Management/Transformity Capital Markets
14 Year Contributor on Fox News' Bulls & Bears /Host @ Fox Business and Founder of ChangeWave Research (now part of S&P NYSE listed Global Research )/NY Times Best Selling Author ChangeWave Investing & ChangeWave Investing 2.0 published by Random House and Managing Member TransMed One LLC and TSIG LLC